Connection
Bradley Warady to Recombinant Proteins
This is a "connection" page, showing publications Bradley Warady has written about Recombinant Proteins.
|
|
Connection Strength |
|
|
|
|
|
0.592 |
|
|
|
-
Mahan JD, Warady BA, Frane J, Rosenfeld RG, Swinford RD, Lippe B, Davis DA. First-year response to rhGH therapy in children with CKD: a National Cooperative Growth Study Report. Pediatr Nephrol. 2010 Jun; 25(6):1125-30.
Score: 0.088
-
Seikaly MG, Waber P, Warady BA, Stablein D. The effect of rhGH on height velocity and BMI in children with CKD: a report of the NAPRTCS registry. Pediatr Nephrol. 2009 Sep; 24(9):1711-7.
Score: 0.083
-
Warady BA, Zobrist RH, Wu J, Finan E. Sodium ferric gluconate complex therapy in anemic children on hemodialysis. Pediatr Nephrol. 2005 Sep; 20(9):1320-7.
Score: 0.064
-
Warady BA, Kausz A, Lerner G, Brewer ED, Chadha V, Brugnara C, Dahl NV, Watkins SL. Iron therapy in the pediatric hemodialysis population. Pediatr Nephrol. 2004 Jun; 19(6):655-61.
Score: 0.059
-
Ng DK, Carroll MK, Kaskel FJ, Furth SL, Warady BA, Greenbaum LA. Patterns of recombinant growth hormone therapy use and growth responses among children with chronic kidney disease. Pediatr Nephrol. 2021 12; 36(12):3905-3913.
Score: 0.048
-
Chanu P, Schaefer F, Warady BA, Schmitt CP, Reigner B, Schnetzler G, Meyer Reigner S, Eisner M, Weichert A, Frey N. Model-based approach for methoxy polyethylene glycol-epoetin beta drug development in paediatric patients with anaemia of chronic kidney disease. Br J Clin Pharmacol. 2020 04; 86(4):801-811.
Score: 0.044
-
Warady B, Watkins SL. Current advances in the therapy of chronic renal failure and end stage renal disease. Semin Nephrol. 1998 May; 18(3):341-54.
Score: 0.039
-
Schwartz ID, Warady BA. Cadaveric renal allograft rejection after treatment with recombinant human growth hormone. J Pediatr. 1992 Oct; 121(4):664-6.
Score: 0.026
-
Warady BA, Sabath RJ, Smith CA, Alon U, Hellerstein S. Recombinant human erythropoietin therapy in pediatric patients receiving long-term peritoneal dialysis. Pediatr Nephrol. 1991 Nov; 5(6):718-23.
Score: 0.025
-
Warady BA. Recombinant human erythropoietin: duplicate publication. Pediatr Nephrol. 1991 Nov; 5(6):763.
Score: 0.025
-
Seikaly MG, Salhab N, Warady BA, Stablein D. Use of rhGH in children with chronic kidney disease: lessons from NAPRTCS. Pediatr Nephrol. 2007 Aug; 22(8):1195-204.
Score: 0.018
-
Mahan JD, Warady BA. Assessment and treatment of short stature in pediatric patients with chronic kidney disease: a consensus statement. Pediatr Nephrol. 2006 Jul; 21(7):917-30.
Score: 0.017
-
Gorman G, Fivush B, Frankenfield D, Warady B, Watkins S, Brem A, Neu A. Short stature and growth hormone use in pediatric hemodialysis patients. Pediatr Nephrol. 2005 Dec; 20(12):1794-800.
Score: 0.016
-
Neu AM, Fivush BA, Warady BA, Watkins SL, Friedman AL, Brem AS, Goldstein S, Frankenfield DL. Longitudinal analysis of intermediate outcomes in adolescent hemodialysis patients. Pediatr Nephrol. 2003 Nov; 18(11):1172-6.
Score: 0.014
-
Schwartz ID, Warady BA, Reddig N, Meek K. Elevated glycosylated hemoglobin in a patient receiving recombinant erythropoietin. Pediatr Nephrol. 1996 Dec; 10(6):809-10.
Score: 0.009
-
Alon US, Allen S, Rameriz Z, Warady BA, Kaplan RA, Harris DJ. Lidocaine for the alleviation of pain associated with subcutaneous erythropoietin injection. J Am Soc Nephrol. 1994 Oct; 5(4):1161-2.
Score: 0.008
-
Kaplan RA, Allen S, Warady BA, Alon US. Effect of lidocaine on the hematopoietic properties of recombinant human erythropoietin in the uremic rat. Pediatr Nephrol. 1994 Aug; 8(4):477-9.
Score: 0.008
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|